 |
| SWITZERLAND: Davos Scales Back Glitz
by Associated Press, New York Times
January 25th, 2009
The economic crisis that emerged out the collapse of securities based on shaky U.S. mortgages poses challenges for the Davos World Economic Forum, an arena that has championed market-driven approaches. |
| US: Research Center Tied to Drug Company
by GARDINER HARRIS, The New York Times
November 24th, 2008
Court documents reveal that Dr. Joseph Biederman, a renowned child psychiatrist, pushed Johnson & Johnson to fund a research center whose goal was “to move forward the commercial goals of J&J.” |
| US: Radio Host Has Drug Company Ties
by GARDINER HARRIS, The New York Times
November 21st, 2008
An influential psychiatrist who was the host of the popular NPR program “The Infinite Mind” earned at least $1.3 million from 2000 to 2007 giving marketing lectures for drugmakers, income not mentioned on the program. |
| US: Eli Lilly settles Zyprexa inquiries in 32 states
by TOM MURPHY and MARLEY SEAMAN, Associated Press
October 7th, 2008
Drugmaker Eli Lilly & Co. cleared another legal cloud hanging over its top-selling drug Zyprexa when it announced a $62 million settlement Tuesday, but several other storms are still brewing for the antipsychotic medication. |
| ARGENTINA: Is GlaxoSmithKline Behaving Badly in Argentina?
by AINA HUNTER, ABC News
September 23rd, 2008
Michaela, a deceased 5 month old, is one of more than 13,000 Argentine children to participate in a clinical study implemented a little more than a year ago by the London-based GlaxoSmithKline, the world's second-largest drug manufacturer. |
| US: Judge to Unseal Documents on the Eli Lilly Drug Zyprexa
by MARY WILLIAMS WALSH, The New York Times
September 5th, 2008
A federal judge in Brooklyn decided on Friday to unseal confidential materials about Eli Lilly’s top-selling antipsychotic drug Zyprexa, citing “the health of hundreds of thousands of people” and “fundamental questions” about the way drugs are approved for new uses. |
| US: U.S. Drug Ads Questioned
by KEITH J. WINSTEIN and SUZANNE VRANICA, The Wall Street Journal
September 3rd, 2008
Consumer advertising for prescription drugs had a negligible impact on sales of products studied by Harvard Medical School researchers -- in a finding that may confound both advertisers and their opponents. |
| US: For Widely Used Drug, Question of Usefulness Is Still Lingering
by ALEX BERENSON, The New York Times
September 1st, 2008
About the only point on which both sides agree is that no one can judge ezetimibe’s safety and benefits for certain without more data, ideally from a clinical trial covering more than 10,000 patients and lasting several years, long enough to show that the drug actually helps patients live longer or avoid heart attacks. |
| US: Mannatech Settles Holder Suits
by SUZANNE SATALINE, Wall Street Journal
June 13th, 2008
Dietary-supplements maker Mannatech Inc. said it settled several lawsuits with shareholders who accused the company of using improper sales tactics to boost the value of the stock. |
| US: Researchers Fail to Reveal Full Drug Pay
by GARDINER HARRIS and BENEDICT CAREY, The New York Times
June 8th, 2008
A world-renowned Harvard child psychiatrist whose work has helped fuel an explosion in the use of powerful antipsychotic medicines in children earned at least $1.6 million in consulting fees from drug makers from 2000 to 2007 but for years did not report much of this income to university officials, according to information given Congressional investigators. |
| US: Merck Wrote Drug Studies for Doctors
by STEPHANIE SAUL, The New York Times
April 16th, 2008
The drug maker Merck drafted dozens of research studies for a best-selling drug, then lined up prestigious doctors to put their names on the reports before publication, according to an article to be published Wednesday in a leading medical journal. |
| US: Drug Makers Near Old Goal: A Legal Shield
by GARDINER HARRIS and ALEX BERENSON, The New York Times
April 6th, 2008
The Bush administration has argued strongly in favor of the doctrine, which holds that the F.D.A. is the only agency with enough expertise to regulate drug makers and that its decisions should not be second-guessed by courts. The Supreme Court is to rule on a case next term that could make pre-emption a legal standard for drug cases. The court already ruled in February that many suits against the makers of medical devices like pacemakers are pre-empted. |
| US: Eli Lilly E-Mail Discussed Unapproved Use of Drug
by ALEX BERENSON, The New York Times
March 17th, 2008
John C. Lechleiter, an Eli Lilly official who is about to become the company's top executive, wrote an e-mail message in 2003 that appears to have encouraged Lilly to promote its schizophrenia medicine Zyprexa for a use not approved by federal drug regulators. |
|
|
